

# The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days

## 1. Executive Summary: The Functional Pivot in Longevity Science

The week spanning November 11 to November 18, 2025, marks a definitive inflection point in the trajectory of longevity science. We are witnessing a fundamental pivot from the theoretical maximization of chronological lifespan to the tangible engineering of functional continuity. While demographic analyses released this week by the University of Wisconsin-Madison suggest that the 20th-century momentum in life expectancy gains has plateaued—creating a "glass floor" of mortality that traditional public health measures can no longer breach<sup>1</sup>—the biomedical research sector has simultaneously delivered a suite of breakthroughs capable of shattering this ceiling.

The theme of this reporting period is "Functional Life Extension." This concept moves beyond the blunt instrument of caloric restriction mimetics toward highly specific, molecularly targeted therapies that decouple biological aging from chronological time. The emerging narrative is one of precision intervention: gene editing for permanent lipid control, kidney-derived metabolites that chemically simulate the systemic benefits of endurance training, and the repurposing of the gut microbiome as an endogenous pharmaceutical factory.

This report synthesizes high-impact data published in *Cell*, *Nature Aging*, *The New England Journal of Medicine*, *PLOS Biology*, and *PNAS* over the last seven days. It integrates clinical trial results regarding Urolithin A and CRISPR-based therapies, indicating that longevity science is graduating from murine models to human application. Furthermore, it analyzes the burgeoning economic landscape, where market projections now estimate the anti-aging sector to reach nearly \$27.5 billion by 2033<sup>3</sup>, driven by a consumer base increasingly

demanding evidence-based interventions over cosmetic solutions.

Current research highlights a transition from treating individual pathologies to targeting the upstream drivers of aging—senescence, mitochondrial dysfunction, and genomic instability—with a level of precision previously unattainable. The following analysis details these developments, categorizing them by mechanism of action and therapeutic potential.

## 2. Metabolic Regulation and the Exercise Mimetic Frontier

The most significant developments of the past week in basic biology cluster around metabolic regulation and the identification of endogenous compounds that can simulate the systemic benefits of lifestyle interventions. The search for an "exercise pill" has long been a holy grail of gerontology; however, new findings have shifted the focus from skeletal muscle to the renal system, fundamentally rearranging our understanding of how physical activity exerts its anti-aging effects.

### 2.1 The Kidney-Muscle Axis: Betaine as a Systemic Regulator

Historically, the study of exercise physiology has focused on myokines—signaling peptides released by contracting skeletal muscle. A groundbreaking study from the Chinese Academy of Sciences, published this week in *Cell*, challenges this muscle-centric view by identifying the kidney as a central command center for exercise-induced longevity.<sup>4</sup>

The research team executed a rigorous longitudinal study involving 13 healthy men followed over six years, utilizing multi-omics tools to track genes, proteins, metabolites, and gut bacteria through various states of rest and exertion.<sup>4</sup> This human data was cross-referenced with murine models to elucidate the molecular pathways involved.

#### 2.1.1 The Mechanism of Action

The study resolves the long-standing "exercise paradox." Acute exercise is known to trigger a survival-oriented inflammatory response and oxidative stress via the IL-6/cortisol pathway.

However, long-term training paradoxically results in suppressed inflammation and enhanced resilience. The researchers discovered that the kidney bridges this gap.

Long-term exercise activates a specific pathway in the kidney that upregulates the production of **betaine**, a metabolite previously known primarily as a methyl donor but underappreciated in the context of systemic signaling. The study demonstrates that betaine acts as a potent signaling molecule that travels systemically to:

1. **Rejuvenate Immune Cells:** Betaine exposure restores the metabolic fitness of lymphoid and myeloid lineages.
2. **Restore Metabolic Balance:** It enhances mitochondrial function and energy utilization across tissues.
3. **Cool Inflammation:** Crucially, betaine suppresses the low-grade, chronic inflammation (inflammaging) associated with sedentary aging.<sup>5</sup>

### 2.1.2 Therapeutic Potential of "Exercise in a Pill"

The most striking finding was that the administration of betaine alone to sedentary mice reproduced many of the anti-aging phenotypes of long-term endurance training. These benefits included sharper cognition, reduced adipose tissue, and calmer systemic inflammation.<sup>4</sup>

This discovery has profound implications for the treatment of frailty and sarcopenia. For populations unable to engage in physical activity due to disability, advanced age, or cardiovascular instability, betaine supplementation could function as a genuine "exercise mimetic." Unlike previous candidates that targeted muscle metabolism directly (often with significant side effects), betaine is a naturally occurring metabolite with a high safety threshold.

#### Comparative Analysis of Exercise Mimetics vs. Physical Activity:

Feature	Physical Exercise (Endurance)	Betaine Supplementation (Mimetic)
Primary Source	Skeletal Muscle Contraction	Kidney Metabolic Output (Exogenous)
Inflammatory Response	Acute spike (IL-6) → Chronic	Direct chronic reduction

	reduction	
<b>Cognitive Effect</b>	Neurogenesis via BDNF	Enhanced cognition via metabolic support
<b>Target Population</b>	Healthy, mobile individuals	Frail, immobilized, or sedentary elderly
<b>Mechanism</b>	Systemic multi-organ crosstalk	Targeted activation of kidney-mediated pathway

## 2.2 Microbiome Engineering: The Colanic Acid Factory

In a parallel development regarding metabolic inputs, researchers publishing in *PLOS Biology* have identified a novel method to turn the gut microbiome into a "longevity factory" using a pharmaceutical trigger. This research represents a shift from "probiotics" (adding bacteria) to "metabolic editing" (forcing existing bacteria to produce beneficial compounds).

The study focuses on **colanic acid**, a bacterial exopolysaccharide that has been previously shown to extend lifespan in *Caenorhabditis elegans* and *Drosophila melanogaster* by promoting mitochondrial fusion and preventing fragmentation.<sup>6</sup>

### 2.2.1 The Cephaloridine Trigger

The innovation lies in the delivery mechanism. The research team discovered that **cephaloridine**, a specific antibiotic, can be used at sub-lethal doses to modulate bacterial behavior rather than kill the population. When gut bacteria are exposed to low doses of cephaloridine, they undergo a stress response that induces the transcription of a specific portion of their genome responsible for synthesizing colanic acids.<sup>6</sup>

This effectively transforms the gut microbiota into miniature chemical plants dedicated to the production of longevity-promoting molecules.

## 2.2.2 Sex-Specific Metabolic Outcomes

The study utilized murine models to test the systemic effects of this induced colanic acid production. The results revealed distinct, sex-specific benefits, highlighting the importance of personalized approaches in longevity interventions:

- **Male Mice:** Exhibited significant improvements in lipid profiles, characterized by increases in High-Density Lipoprotein (HDL) and decreases in Low-Density Lipoprotein (LDL).
- **Female Mice:** Showed marked reductions in fasting insulin levels and improved glucose homeostasis.<sup>6</sup>

## 2.2.3 Safety and Non-Absorption

A critical advantage of this approach is the pharmacokinetic profile of cephaloridine. When ingested orally, cephaloridine is not absorbed by the host's gastrointestinal tract. This means the drug acts exclusively on the microbiome to stimulate beneficial compound production without entering the host's bloodstream or affecting systemic tissues.<sup>6</sup> This "luminal-only" activity eliminates the risk of systemic toxicity and side effects common with absorbed pharmaceuticals, representing a safer paradigm for chronic longevity interventions.

# 3. Mitochondrial Rejuvenation and Immunosenescence

Moving from preclinical animal studies to human efficacy, the past week has provided robust clinical data validating mitochondrial interventions. The deterioration of mitochondrial function is a hallmark of aging, leading to cellular energy deficits that impair high-demand systems like the immune system and the brain.

## 3.1 Urolithin A: Clinical Validation in the "MitoImmune" Study

Timeline (Amazentis SA), a Swiss longevity biotech company, released pivotal results this week

from the **MitoImmune** clinical trial, published in the prestigious journal *Nature Aging*.<sup>7</sup> The study focused on **Urolithin A (UA)**, a postbiotic compound known to stimulate mitophagy—the selective autophagy of defective mitochondria.

While UA has previously shown efficacy in improving muscle strength, this study is the first to demonstrate its profound impact on the aging immune system in humans.

### 3.1.1 Trial Design and Outcomes

The randomized, placebo-controlled trial involved healthy middle-aged adults receiving a daily oral dose of 1000 mg of Urolithin A for a duration of four weeks.<sup>9</sup>

- **Primary Finding:** UA supplementation significantly improved the bioenergetics of T cells. Aging typically leads to T cell exhaustion, where these immune defenders lose the metabolic capacity to proliferate and respond to pathogens. UA restored this capacity by clearing dysregulated mitochondria.
- **Biomarkers:** Participants in the treatment group showed a reduction in inflammatory markers, specifically C-reactive protein (CRP), and an increase in the circulation of naïve T cells, which are essential for responding to new antigenic threats.<sup>10</sup>
- **Significance:** This provides the first direct clinical evidence that a mitochondrial intervention can reverse aspects of immunosenescence. By rejuvenating the power plants of immune cells, UA enhances the body's resilience against infections and reduces the burden of sterile inflammation (inflammaging) that drives chronic disease.

## 3.2 Expanding the Frontier: The CLARITY Trial

Building on the success of the MitoImmune study and previous work demonstrating a 12% increase in muscle strength<sup>11</sup>, Timeline announced the launch of the **CLARITY** trial this week.<sup>7</sup> This represents the company's 25th clinical trial and is the largest study to date investigating the effects of Urolithin A on brain health.

The CLARITY trial aims to determine if the mitochondrial rejuvenation observed in muscle and immune cells translates to neurons and glial cells. Given that the brain is the most energy-demanding organ in the body, the hypothesis is that enhancing mitophagy via UA will improve cognitive function, memory consolidation, and potentially delay the onset of neurodegenerative conditions.

## Urolithin A Clinical Development Landscape:

Study Name	Target System	Status	Key Outcome / Objective
<b>Muscle Health</b>	Skeletal Muscle	Completed	12% increase in muscle strength; improved VO2 max <sup>11</sup>
<b>MitoImmune</b>	Immune System	<b>Published (Nov 2025)</b>	Restored T-cell metabolism; reduced inflammation <sup>7</sup>
<b>CLARITY</b>	Brain / CNS	<b>Recruiting (Nov 2025)</b>	Efficacy in cognitive function and neuroprotection <sup>7</sup>

## 4. Genetic Editing: The Era of "One-and-Done" Longevity

While metabolic interventions like Betaine and Urolithin A offer gradual improvements through daily supplementation, genetic engineering results released this week demonstrate the potential for curative, single-dose longevity treatments. The ability to permanently rewrite the genetic code to eliminate risk factors is moving from theoretical possibility to clinical reality.

### 4.1 CRISPR Therapeutics and Cardiovascular Longevity (CTX310)

In a landmark presentation at the American Heart Association Scientific Sessions, simultaneously published in *The New England Journal of Medicine*, CRISPR Therapeutics revealed Phase 1 data for **CTX310**, an *in vivo* CRISPR-Cas9 gene-editing therapy.<sup>12</sup> This data represents a massive leap forward in the prevention of cardiovascular disease, the leading

killer of aging populations.

#### 4.1.1 Target and Mechanism

CTX310 targets the *ANGPTL3* (angiopoietin-like 3) gene in the liver. The ANGPTL3 protein is a key regulator of lipid metabolism that inhibits enzymes responsible for clearing triglycerides and cholesterol from the blood. People with naturally occurring loss-of-function mutations in *ANGPTL3* have exceptionally low levels of lipids and are virtually immune to coronary artery disease, with no apparent negative health consequences. CTX310 aims to mimic this natural mutation.

#### 4.1.2 Clinical Efficacy and Safety

The Phase 1 trial involved 15 participants with severe, refractory dyslipidemia. The results of a single intravenous infusion were dramatic and durable:

- **ANGPTL3 Reduction:** A mean reduction of plasma ANGPTL3 protein by approximately 73%, with some patients achieving nearly 90% reduction.
- **Lipid Profile:** Consequently, LDL cholesterol dropped by a mean of 49% (up to 87% in best responders) and triglycerides fell by a mean of 55% (up to 84%).<sup>13</sup>
- **Safety Profile:** The therapy was generally well-tolerated. There were two serious adverse events (SAEs) and three infusion-related reactions reported, but no dose-limiting toxicities.<sup>15</sup> This safety profile is considered acceptable for a Phase 1 trial, particularly given the severity of the condition being treated.

#### 4.1.3 Implications for Longevity

The implications of CTX310 extend far beyond the treatment of rare dyslipidemias. This therapy represents a proof-of-concept for a "vaccine" against heart disease. By permanently editing the genome to maintain optimal lipid profiles, CTX310 shifts the treatment paradigm from chronic daily management (statins, which have adherence issues and side effects) to a permanent genetic upgrade.

From a longevity perspective, minimizing vascular plaque accumulation starting in mid-life could potentially eliminate the primary driver of mortality for decades, significantly extending

healthspan. The financial model of such a therapy remains to be seen, but the split of program costs and profits between Vertex Pharmaceuticals and CRISPR Therapeutics suggests a high-value commercial strategy is being developed.<sup>16</sup>

## 5. Immunosenescence and Senolytics: Paradoxes and Progress

The immune system's role in aging was a dominant theme in this week's literature, presenting both unexpected paradoxes in basic biology and progress in clinical applications for neurodegenerative disease.

### 5.1 The T Helper Cell Paradox in Supercentenarians

A groundbreaking study published in *Nature Aging* by researchers at Ben-Gurion University of the Negev challenges the dogma that all immune accumulation in old age is deleterious. The team identified a specific subset of **T helper cells** (CD4+) that accumulates significantly with age.<sup>17</sup>

#### 5.1.1 Cytotoxic Capabilities

Typically, T helper cells orchestrate immune responses but do not kill infected cells directly. However, the researchers found that this specific age-associated subset acquires potent cytotoxic (killing) capabilities. Their primary target is not viruses, but senescent cells—the damaged "zombie" cells that accumulate in tissues and drive aging via the secretion of inflammatory factors (SASP).

These T cells effectively function as the body's endogenous senolytics, patrolling tissues to identify and eliminate senescent cells.

#### 5.1.2 The Supercentenarian Connection

The clinical relevance of this finding was solidified by analyzing the blood of

supercentenarians (individuals aged 110 and older). The study found that this specific cytotoxic T-helper subset was highly abundant in these exceptional agers.

- **Insight:** This suggests that successful aging is not just about preventing immune decline, but about the adaptive *expansion* of specific immune populations that can manage the burden of cellular senescence.
- **Therapeutic Strategy:** Current immune therapies often aim to rejuvenate the immune system to a "youthful" state. This study suggests that for the elderly, a more effective strategy might be to boost this specific "aged" T-cell phenotype to enhance the clearance of senescent cells.<sup>17</sup>

## 5.2 Senolytics in Alzheimer's Disease: The SToMP-AD Pilot

On the clinical front, the translation of senolytic drugs (compounds that kill senescent cells) into human therapies achieved a milestone. A pilot study from Harvard Medical School and Hebrew SeniorLife, titled **SToMP-AD** (Senolytic Therapy to Modulate Progression of Alzheimer's Disease), released promising data regarding the combination of **Dasatinib and Quercetin (D+Q)**.<sup>18</sup>

### 5.2.1 Cognitive Improvements and Biomarkers

The study administered D+Q to older adults with early-stage Alzheimer's disease. While the sample size was small (pilot study), the results indicated safety and blood-brain barrier penetrance.

- **Cognitive Gain:** The study utilized the Montreal Cognitive Assessment (MoCA) to measure cognitive function. In participants with the lowest baseline MoCA scores (indicating significant impairment), there was a statistically significant increase of **2.0 points** following treatment.<sup>18</sup>
- **Mechanism:** The researchers observed a correlation between the reduction of **TNF-alpha** (a key pro-inflammatory cytokine in the SASP) and the improvement in cognitive scores. This links the reduction of systemic inflammation directly to cognitive recovery.
- **Next Steps:** The success of this pilot has triggered further funding, including a Gap III Grant, to expand the research. It also utilizes the "SenMayo" panel of biomarkers to track senescent cell burden, validating a new diagnostic tool for future trials.<sup>19</sup>

## 5.3 The Cancer-Aging Paradox

A Stanford University study published in *Nature Aging* has overturned a central tenet of oncology and aging. While cancer risk generally rises with age, the study found that **very old mice develop fewer and smaller lung tumors** than younger counterparts.<sup>21</sup>

- **Findings:** The aging lung environment appears to suppress tumor progression. This is likely due to changes in the extracellular matrix and the immune microenvironment that, while less efficient at repair (leading to aging), become hostile to the rapid cell division required for tumorigenesis.
- **Relevance:** This "silver lining" of cellular aging suggests that mechanisms evolving to suppress tissue regeneration in old age (to prevent exhaustion) may inadvertently act as potent tumor suppressors. Understanding this mechanism could lead to new cancer therapies that mimic the "aged" tissue environment to stifle tumor growth.<sup>22</sup>

## 6. Proteostasis and Molecular Regulation

Beyond genetics and metabolism, the regulation of protein function (proteostasis) remains a critical pillar of longevity research.

### 6.1 The Sirt6 and Hydrogen Sulfide Regulatory Loop

Research from Bar-Ilan University and the National Institute on Aging, published in *PNAS*, has elucidated the mechanism behind **Sirt6**, a protein long dubbed a "longevity gene." While Sirt6 overexpression is known to extend lifespan, the *how* has been elusive. The new study reveals that Sirt6 regulates **hydrogen sulfide (H2S)** homeostasis.<sup>23</sup>

#### 6.1.1 The "Goldilocks" Regulation

Hydrogen sulfide is a gasotransmitter vital for vascular health, acting to relax blood vessels

(vasodilation) and promote angiogenesis. However, it is toxic in high concentrations. The study demonstrates that Sirt6 acts as a metabolic thermostat—Professor Haim Cohen describes it as having "one foot on the gas and the other on the brake." Sirt6 recruits enzymes to upregulate H2S when beneficial for tissue repair and downregulate it to prevent toxicity.<sup>23</sup>

### 6.1.2 Clinical Application

This finding identifies H2S regulation as a key therapeutic target for vascular aging. By manipulating Sirt6 activity or using H2S donors that mimic this regulatory precision, it may be possible to restore endothelial function in the elderly, preventing hypertension and atherosclerosis.<sup>24</sup> Furthermore, the tight correlation between Sirt6 activity and H2S levels suggests that measuring H2S capacity could serve as a novel biomarker for "internal regulatory age".<sup>23</sup>

## 7. Diagnostics, AI, and Data Infrastructure

The translation of longevity science into practice relies on the ability to measure aging accurately. The past week saw major releases in data infrastructure and diagnostic tools.

### 7.1 The 300TB Baseline: Precision Aging Network

The **Precision Aging Network**, led by the University of Arizona, announced the imminent release of a massive **300-terabyte dataset** focused on *normal* cognitive aging. Hosted on the CyVerse cloud platform, this data will be publicly available to researchers starting late November.<sup>25</sup>

Unlike datasets focused on pathology (Alzheimer's), this repository maps the trajectory of the healthy aging brain. It provides a critical "control group" for the entire field, allowing researchers to distinguish between benign age-related changes and the earliest prodromal signs of disease.

## 7.2 AI and the Steroid Clock

Simultaneously, researchers at **Osaka University** unveiled an AI-powered model capable of determining biological age from just **five drops of blood**. The model utilizes liquid chromatography-mass spectrometry (LC-MS) to analyze **22 key steroid hormones** and their intermediates.<sup>26</sup>

Traditional hormonal assays fluctuate wildly due to circadian rhythms and stress. However, the AI model filters out this noise to identify deep, stable patterns of steroid decline and imbalance. This offers a new, minimally invasive "aging clock" that provides actionable insights into endocrine health, potentially rivaling DNA methylation clocks in clinical utility.

## 7.3 The Consensus on Biomarkers

These developments were contextualized by the announcement of the **Biomarkers of Aging Conference** at Harvard Medical School. The field is coalescing around the need for standardized metrics. With tools like the "SenMayo" panel for senescence<sup>19</sup>, the Osaka steroid clock, and proteomic signatures from companies like Alamar Bio<sup>27</sup>, we are approaching a consensus on how to measure the efficacy of longevity interventions in real-time.

### Emerging Biomarker Platforms:

Platform / Tool	Target Analyte	Developer / Institution	Application
<b>Steroid AI Clock</b>	22 Steroid Hormones	Osaka University	Endocrine aging; minimally invasive
<b>SenMayo Panel</b>	SASP Factors (TNF- $\alpha$ , etc.)	Mayo Clinic / Harvard	Senescent cell burden tracking
<b>Precision Aging Data</b>	Neuroimaging / Cognition	Univ. of Arizona / NIA	Baseline for normal cognitive aging

<b>H2S Capacity</b>	Hydrogen Sulfide / Sirt6	Bar-Ilan University	Vascular and metabolic regulatory age
---------------------	--------------------------	---------------------	---------------------------------------

## 8. Market Dynamics, Investment, and Conferences

The longevity market is reacting to these scientific signals with robust growth forecasts and high-profile industry gatherings.

### 8.1 Market Valuation and Growth

Reports released this week project the U.S. anti-aging products market to reach \$27.44 billion by 2033, growing at a CAGR of 8.0%.<sup>3</sup> Globally, the market is forecasted to surpass \$421 billion by 2030.

This growth is fueled by a transition in consumer behavior. The demand is shifting from superficial skincare to "longevity-focused health," driven by the clinical validation of supplements (like Urolithin A) and the mainstreaming of preventative medicine.

### 8.2 Investment Landscape

The investment climate remains discerning. While early "hype" companies like Unity Biotechnology have faced stock market challenges (shares devalued significantly from 2018 highs), capital is flowing toward companies with rigorous clinical data.<sup>29</sup> The success of CRISPR Therapeutics (CRSP) with CTX310 highlights the market's appetite for biotech firms that can deliver verifiable disease-modifying results.

### 8.3 Global Summits

The industry's momentum is visible in the scale of its conferences:

- **LongevityFest 2025:** Scheduled for December in Las Vegas, this event by the American Academy of Anti-Aging Medicine (A4M) will host over 500 companies, signaling the massive commercial ecosystem building around longevity.<sup>30</sup>
- **Tech for Longevity (Paris):** Moving from Station F to the Grand Palais, this summit is integrating with the "Adopt AI" summit, reflecting the inseparable link between artificial intelligence and modern drug discovery in the longevity space.<sup>31</sup>

## 9. Societal and Ethical Considerations

### 9.1 The "Life Expectancy Ceiling"

A sobering counter-narrative to the week's breakthroughs was the analysis from the University of Wisconsin-Madison.<sup>1</sup> The study asserts that the era of radical life expectancy extension via standard public health (vaccines, sanitation, basic cardiac care) is over. The authors argue that human longevity is hitting a "glass floor," and that living to 100 will not become a norm for existing generations using current medical paradigms.

Analysis: This report validates the necessity of the "Geroscience" approach. If standard medicine has maximized its potential, the only path to further extension is through the radical interventions detailed in Sections 2 and 3 (gene editing, senolytics, metabolic reprogramming).

### 9.2 The Ethics of the "Exercise Pill"

The discovery of betaine as an exercise mimetic<sup>4</sup> raises distinct ethical questions regarding the "medicalization of lifestyle." Critics argue that if a pill can mimic the metabolic benefits of running, the incentive for physical activity—which has benefits beyond chemistry, such as psychological resilience and locomotor skill—may diminish.

However, bioethicists and clinicians argue that for the aging population with sarcopenia or osteopenia, the ethical imperative supports the development of these mimetics. For a patient with a fractured hip or severe heart failure, an "exercise pill" is not a cheat; it is a lifeline that prevents the rapid physiological decline associated with bed rest.<sup>32</sup>

## 9.3 Cognitive Reserve and Multilingualism

Finally, a study of 86,000 people published in *Nature Aging* highlighted a non-pharmacological tool: **multilingualism**. Speaking more than one language was found to halve the risk of accelerated cognitive aging.<sup>33</sup> This serves as a reminder that while biotechnology advances, "cognitive reserve"—built through lifelong learning and complex mental activity—remains a potent, accessible, and ethical tool for preserving functional life.

## 10. Future Directions and Strategic Outlook

The events of the last seven days suggest three immediate future directions for the field:

1. **Combinatorial Protocols:** The synergy between immune-boosting therapies (Urolithin A) and senescence-clearing mechanisms (T-cell modulation, D+Q) suggests that future clinical protocols will be combinatorial. Therapies will likely pair a metabolic agent to support healthy cells with a senolytic agent to clear damaged ones.
2. **Microbiome Pharmacology:** The success of cephaloridine in inducing colanic acid production<sup>6</sup> will likely spur a new class of drugs designed to "farm" the microbiome. We expect to see more "non-absorbed" small molecules that target bacterial transcription to elicit systemic host benefits.
3. **Preventive Gene Editing:** The safety profile of CTX310<sup>12</sup> opens the door for gene editing to be used as a primary preventive tool. We are moving toward a future where a single infusion in mid-life could permanently inoculate individuals against the primary drivers of age-related mortality, such as atherosclerosis.

In conclusion, the research from November 11–18, 2025, provides a blueprint for overcoming the "life expectancy ceiling." By manipulating the kidney-muscle axis, editing lipid-regulating genes, and harnessing the immune system's natural anti-aging capacities, science is constructing the functional scaffolding necessary for significant human life extension. The shift from "lifespan" to "functional healthspan" is no longer a slogan; it is an engineering problem that is actively being solved.

### Works cited

1. Life expectancy gains have slowed sharply, study finds | ScienceDaily, accessed November 18, 2025, <https://www.sciencedaily.com/releases/2025/10/251026021749.htm>
2. New research reveals longevity gains slowing, life expectancy of 100 unlikely, accessed November 18, 2025,

- <https://lafollette.wisc.edu/news/new-research-reveals-longevity-gains-slows-life-expectancy-of-100-unlikely/>
3. Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach \$27 Billion By 2033 - Barchart.com, accessed November 18, 2025, <https://www.barchart.com/story/news/36183006/longevity-focused-health-fueling-u-s-anti-aging-products-market-projected-to-reach-27-billion-by-2033>
  4. Scientists find a molecule that mimics exercise and slows aging | ScienceDaily, accessed November 18, 2025, <https://www.sciencedaily.com/releases/2025/11/251113071620.htm>
  5. Natural compound mimics exercise's anti-aging benefits – no gym needed - New Atlas, accessed November 18, 2025, <https://newatlas.com/fitness/surprise-molecule-exercise/>
  6. Scientists Discover How To Turn Gut Microbiome Into a Longevity ..., accessed November 18, 2025, <https://scitechdaily.com/scientists-discover-how-to-turn-gut-microbiome-into-a-longevity-factory/>
  7. Timeline Continues to Build the Most Clinically Researched Longevity Products Targeting Immune, Brain and Muscle Aging, accessed November 18, 2025, <https://www.biospace.com/press-releases/timeline-continues-to-build-the-most-clinically-researched-longevity-products-targeting-immune-brain-and-muscle-aging>
  8. Urolithin A recharges aging immune cells and boosts mitochondrial fitness in midlife adults, accessed November 18, 2025, <https://www.news-medical.net/news/20251103/Urolithin-A-recharges-aging-immune-cells-and-boosts-mitochondrial-fitness-in-midlife-adults.aspx>
  9. New Study: Urolithin A Revitalizes an Aging Immune System - Timeline, accessed November 18, 2025, <https://www.timeline.com/blog/new-study-urolithin-a-revitalizes-an-aging-immune-system>
  10. Urolithin Supplement Counters Immune System Aging, New Human Trial Shows - NAD.com, accessed November 18, 2025, <https://www.nad.com/news/urolithin-supplement-counters-immune-system-aging-new-human-trial-shows>
  11. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults - NIH, accessed November 18, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9133463/>
  12. CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia - Consult QD, accessed November 18, 2025, <https://consultqd.clevelandclinic.org/crispr-cas9-gene-editing-for-refractory-dyslipidemia>
  13. CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering, accessed November 18, 2025, <https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-positive-phase-1-clinical-data>

14. Top news stories from AMA Morning Rounds®: Week of Nov. 10, 2025, accessed November 18, 2025,  
<https://www.ama-assn.org/about/publications-newsletters/top-news-stories-ama-morning-rounds-week-nov-10-2025>
15. 'Unprecedented': Single dose of new gene-editing therapy lowers cholesterol, triglycerides, accessed November 18, 2025,  
<https://cardiovascularbusiness.com/topics/clinical/heart-health/unprecedented-single-dose-new-gene-editing-therapy-lowers-cholesterol-triglycerides>
16. CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3, accessed November 18, 2025,  
<https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial>
17. Neuroscientists find immune cells that may slow aging | ScienceDaily, accessed November 18, 2025,  
<https://www.sciencedaily.com/releases/2025/11/251115095926.htm>
18. New Harvard-Mayo-Cedars-Sinai Joint Study Confirms Safety of Anti-Aging Senolytic Treatment - NMN.com, accessed November 18, 2025,  
<https://www.nmn.com/news/new-harvard-study-anti-aging-senolytics-are-safe-for-seniors-with-memory-loss>
19. Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction - Oxford Academic, accessed November 18, 2025,  
<https://academic.oup.com/edrv/article/45/5/655/7631421>
20. Pilot Study Suggests Treatment May Improve Cognition in Older Adults at Risk for Alzheimer's Disease | Hebrew SeniorLife, accessed November 18, 2025,  
<https://www.hebrewseniorlife.org/news/pilot-study-suggests-treatment-may-improve-cognition-older-adults-risk-alzheimers-disease>
21. Stanford Scientists Discover Aging May Suppress Cancer, Not Fuel It - SciTechDaily, accessed November 18, 2025,  
<https://scitechdaily.com/stanford-scientists-discover-aging-may-suppress-cancer-not-fuel-it/>
22. Extreme age protects against cancer in Stanford University mouse study, accessed November 18, 2025,  
<https://med.stanford.edu/news/all-news/2025/11/extreme-age-cancer.html>
23. Scientific Study Unlocks Potential for New Anti-Aging - Israel.com, accessed November 18, 2025,  
<https://israel.com/health/scientific-study-unlocks-potential-for-new-anti-aging-therapies/>
24. Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure, accessed November 18, 2025,  
<https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.122.321326>
25. Precision Aging Network data release will open new pathways for ..., accessed November 18, 2025,  
<https://news.arizona.edu/news/precision-aging-network-data-release-will-open-new-pathways-healthy-aging-research>

26. New AI model reveals your true biological age from 5 drops of blood | ScienceDaily, accessed November 18, 2025, <https://www.sciencedaily.com/releases/2025/03/250314170424.htm>
27. Biomarkers of Aging 2025 Conference - Alamar Biosciences, accessed November 18, 2025, <https://alamarbio.com/biomarkers-of-aging-2025-conference/>
28. Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach \$27 Billion By 2033, accessed November 18, 2025, <https://www.globenewswire.com/news-release/2025/11/18/3190051/0/en/Longevity-Focused-Health-Fueling-U-S-Anti-Aging-Products-Market-Projected-to-Reach-27-Billion-By-2033.html>
29. Longevity Startup Funding Sees Fewer Moonshots, But Plenty Of Buzzy Investments, accessed November 18, 2025, <https://news.crunchbase.com/venture/longevity-startup-funding-2025-newlimit-data/>
30. A4M Unveils Next Frontier in Longevity Science with LongevityFest 2025, accessed November 18, 2025, <https://www.manilatimes.net/2025/11/18/tmt-newswire/globenewswire/a4m-unveils-next-frontier-in-longevity-science-with-longevityfest-2025/2226577>
31. Tech for Longevity returns to Paris in 2025, accessed November 18, 2025, <https://longevity.technology/news/tech-for-longevity-returns-to-paris-in-2025/>
32. Researchers Highlight Ethical Concerns When Clinical Trials Are Cut Short: 2025, accessed November 18, 2025, <https://nursing.iu.edu/news-events/vital-signs/2025/2025-10-researchers-highlight-ethical-concerns-when-clinical-trials-are-cut-short.html>
33. [Research Press Release] Ageing: Multilingualism may protect against accelerated ageing (Nature Aging), accessed November 18, 2025, <https://www.natureasia.com/en/info/press-releases/detail/9145>